A semi‐mechanistic model based on glutathione depletion to describe intra‐individual reduction in busulfan clearance-Reference-Cited by-同舟云学术

A semi‐mechanistic model based on glutathione depletion to describe intra‐individual reduction in busulfan clearance

Published:2020-03-10 Issue:8 Volume:86 Page:1499-1509
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Langenhorst Jurgen B.¹²^ORCID,Boss Jill³,Kesteren Charlotte⁴,Lalmohamed Arief⁵,Kuball Jürgen¹⁶,Egberts Antoine C. G.⁵⁷,Boelens Jaap Jan⁸,Huitema Alwin D. R.⁵⁹,Maarseveen Erik M.⁵

Affiliation:

1. Laboratory of Translational ImmunologyUniversity Medical Centre Utrecht, Utrecht University Utrecht The Netherlands

2. Model‐informed Drug Development Consultant, Pharmetheus AB Uppsala Sweden

3. Hospital Pharmacy, St Jansdal Hospital Harderwijk The Netherlands

4. Hospital Pharmacy, Albert Schweitzer Hospital Dordrecht The Netherlands

5. Department of Clinical Pharmacy, University Medical Centre UtrechtUtrecht University Utrecht The Netherlands

6. Department of Hematology, University Medical Centre UtrechtUtrecht University Utrecht The Netherlands

7. Department of Pharmacoepidemiology & Clinical Pharmacology, Faculty of ScienceUtrecht University, Utrecht, The Netherlands

8. Stem Cell Transplant and Cellular Therapies; Pediatrics, Memorial Sloan Kettering Cancer Centre New York City, New York USA

9. Department of Pharmacy & PharmacologyNetherlands Cancer Institute Amsterdam The Netherlands

Funder

Stichting Kinderen Kankervrij

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14256

Reference40 articles.

1. Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors

2. Busulfan in Hematopoietic Stem Cell Transplantation

3. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

4. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis

5. Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Busulfan Exposure Target Attainment in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: A Single Day Versus a Multiple Day Therapeutic Drug Monitoring Regimen;Transplantation and Cellular Therapy;2024-07

3. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients;Therapeutic Drug Monitoring;2024-06-14

4. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing;Journal of Pharmacokinetics and Pharmacodynamics;2024-03-23

5. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle;Frontiers in Immunology;2023-12-22